AltTox.org

Non-animal Methods for Toxicity Testing

In the Spotlight
Meetings & Events

References


Last Updated: December 6, 2007
Print |
Email
  1. Fang, N., et al. (2005). Sub-diffraction-limited optical imaging with a silver superlens. Science. 308, 534-537.
  2. Leatherdale, C.A. et al. (2002). On the Absorption Cross Section of CdSe Nanocrystal Quantum Dots. Phys. Chem. B. 106, 7619-7622.
  3. Sin, A., et al. (2004). The Design and Fabrication of Three-Chamber Microscale Cell Culture Analog Devices with Integrated Dissolved Oxygen Sensors. Biotechnol. Prog. 20, 338-345.
  4. Atterwill C.K., et al. (1999). Brain spheroid and other organotypic culture systems in in vitro neurotoxicology. In Neurotoxicology in vitro (Penreath VW) ed) pp213-238. Taylor and Francis.
  5. Expert Group on Phase One Clinical Trials: Final report
  6. Critical Path Initiative (US Food and Drug Administration)
  7. Predictomics
  8. Anglicheau, D., et al. (2007). Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics. 8, 835-849.
  9. Paoluzzi, L. et al. (2004). Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN 38. J. Clin. Pharm. 44, 854–860.
  10. Niemi, M. (2007) Role of OATP transporters in the disposition of drugs Pharmacogenomics 8 787-802.
  11. Guidance for Industry: Pharmacogenomic Data Submissions. U.S. Department of Health and Human Services, Food and Drug Administration, CDER, CBER, CDRH (2003).
  12. Mount Isa Mines Ltd v Pusey (1970) 125 CLR 383, 395